While conventional LNPs are limited by liver accumulation, Starna Therapeutics utilizes rational design to engineer carriers that bypass hepatic uptake.

This breakthrough significantly enhances bioavailability in non-hepatic tissues, expanding the therapeutic landscape for RNA medicines beyond liver targets.

Powered by deep expertise in lipid and combinatorial chemistry, we have synthesized a proprietary library containing thousands of distinct lipid entities. By integrating AI-driven design with high-throughput wet-lab screening, we rapidly identify novel formulations with superior tissue specificity and high translational potential.

Our platform achieves precise targeting of distinct cell populations through surface functionalization with specific ligands (e.g., antibodies, proteins). This active targeting strategy creates new opportunities for next-generation therapies, including in vivo CAR-T cell reprogramming.